Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 14, 2017

Study Completion Date

September 14, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

QR-010

Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton

DRUG

Placebo

Normal Saline

Trial Locations (27)

13353

Charité Universitätsmedizin Berlin, Berlin

15006

Motol University Hospital, Prague

17033

Penn State Milton S. Hershey Medical Center, Hershey

29425

Medical University of South Carolina, Charleston

30625

Medizinische Hochschule Hannover, Hanover

37134

Azienda Ospedaliera Universitaria Integrata di Verona, Verona

44300

HGRL Chu Nantes, Nantes

60611

Northwestern University, Chicago

66160

University of Kansas Medical Center Research Institute, Kansas City

Nationwide Children's Hospital, Columbus

75390

University of Texas Southwestern Medical Center, Dallas

75743

Hopital Necker- Enfants Malades, Paris

80336

Munich U. Hospital, Cystic Fibrosis Center for Adults, Munich

90033

University of Southern California USC - Keck School of Medicine, Los Angeles

940304

Stanford University, Palo Alto

02114

Massachusetts General Hospital, Boston

02115

Boston Children's Hospital, Boston

63110-1032

Washington University School of Medicine, St Louis

98195-6522

University of Washington Medical Center, Seattle

01090

Universitair Ziekenhuis Brussel, Brussels

03000

University of Leuven, Leuven

T2N 4N1

University of Calgary (Health Sciences Centre), Calgary

02100

Cystic Fibrosis Center Rigshospitalet, Copenhagen

08035

Hospital Vall D'Hebron, Barcelona

BT9 6AD

Celerion, Belfast

SW3 6NP

Royal Brompton Hospital, London

SO16 6YD

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

European Commission

OTHER

lead

ProQR Therapeutics

INDUSTRY